Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Figure 2 Urinary albumin-to-creatinine ratio at week 0 and week 8 of the experiment in non-diabetic db/+ mice and diabetic db/db mice, treated with vehicle or empagliflozin. The data are presented as medians, lower and upper quartiles. ^aP < 0.001 vs non-diabetic control (db/+ mice); ^bP < 0.001 vs placebo(Mann-Whitney U-test); ^cP < 0.01 vs week 8 (Wilcoxon test). EMPA: Empagliflozin.